title: Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment for CML may necessitate delay in harvesting marrow cells for autografting.
abstract: Fourteen patients with chronic myelogenous leukemia in chronic phase who had achieved hematological remission after alpha-interferon (IFN) therapy were evaluated for their ability to form hemopoietic colonies in vitro. Patients were studied both before and after discontinuation of IFN to assess the optimal timing for a further therapeutic approach consisting of stem cell collection followed by autologous bone marrow transplantation (ABMT). Before stopping IFN a profound inhibition of CFU-GM and BFU-E growth was observed. The numbers of CFU-GM and BFU-E in the bone marrow recovered to 50 per 2 x 10(5) cells plated at a median of 158 and 122 days, respectively, after stopping IFN. At that time, 12 patients were submitted to stem cell harvest and subsequently to ABMT. All patients showed complete engraftment and hematological reconstitution; cytogenetic improvement was observed in eight (67%) cases; two patients displayed complete disappearance of the Ph1 chromosome, confirmed at the molecular level. Eleven of the 12 patients are still in hematological remission at a median of 18 months from autografting and a median of 48 months from diagnosis.
authors.affiliation: Department of Human Biopathology, University La Sapienza, Rome, Italy.
authors.forename: P
authors.initials: P
authors.lastname: De Fabritiis
authors.forename: A
authors.initials: A
authors.lastname: Sandrelli
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: G
authors.initials: G
authors.lastname: Alimena
authors.forename: E
authors.initials: E
authors.lastname: Montefusco
authors.forename: F
authors.initials: F
authors.lastname: Lo Coco
authors.forename: L
authors.initials: L
authors.lastname: De Felice
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D016026:Bone Marrow Transplantation / Q000379:methods; D004247:DNA / Q000032:analysis / Q000235:genetics; D004912:Erythrocytes / Q000187:drug effects / Q000473:pathology; D006098:Granulocytes / Q000187:drug effects / Q000473:pathology; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins / Q000235:genetics; D051562:Proto-Oncogene Proteins c-bcr
chemical_list: D007370:Interferon Type I; D011518:Proto-Oncogene Proteins; D004247:DNA; D011505:Protein-Tyrosine Kinases; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr